Clinical Trial Update: Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3") [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the Crux Inferior Vena Cava Filter System 3 (RETRIEVE 3) has completed, assessing its use in preventing pulmonary embolism. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Crux Inferior Vena Cava Filter System 3

Snippet

Sponsor: Crux Biomedical | Conditions: Pulmonary Embolism | Phase 3 | Status: COMPLETED